机译:肾细胞癌患者白细胞介素2联合四种不同剂量的bryostatin-1的随机II期临床试验
Department of Medicine Section of Hematology/Oncology The University of Chicago;
Department of Medicine Section of Hematology/Oncology The University of Chicago;
Department of Health Studies The University of Chicago;
Nevada Cancer Institute;
Oncology/Hematology Associates;
Oncology/Hematology Associates;
Oncology Care Associates;
Department of Medicine Section of Hematology/Oncology The University of ChicagoUniversity of Chicago Cancer Research Center The University of Chicago;
Department of Medicine Section of Hematology/Oncology The University of ChicagoDepartment of Pathology The University of Chicago;
Department of Medicine Section of Hematology/Oncology The University of ChicagoUniversity of Chicago Cancer Research Center The University of ChicagoDepartment of Surgery Section of Urology The University of Chicago;
Bryostatin; Interleukin-2; Renal cell cancer; Phase II trial;
机译:转移性肾细胞癌患者大剂量白细胞介素2与皮下白细胞介素2和干扰素的III期随机试验。
机译:转移性肾细胞癌患者大剂量白细胞介素2与皮下白细胞介素2和干扰素的III期随机试验。
机译:CD8(+)肿瘤浸润淋巴细胞与重组白介素-2联合用于转移性肾细胞癌的多中心,随机,III期试验。
机译:在转移性肾细胞癌中设计III期试验:新标准是什么?
机译:涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募,保留和依从性报告。
机译:开放标签随机多中心II期研究通过剂量给药方案(剂量修改或剂量中断)评估舒尼替尼在晚期或转移性肾细胞癌患者中的疗效和耐受性:SURF试验的研究方案
机译:高剂量白细胞介素-2联合可溶性p75肿瘤坏死因子受体免疫球蛋白G嵌合体治疗晚期黑色素瘤和肾细胞癌的随机安慰剂对照临床试验